Treatment of Graves’ disease with methimazole in children alters the proliferation of Treg cells and CD3+ T lymphocytes by Klatka, Maria et al.
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 52, No. 1, 2014
pp. 69–77
©Polish Society for Histochemistry and Cytochemistry
Folia Histochem Cytobiol. 2014
10.5603/FHC.2014.0008
www.fhc.viamedica.pl
ORIGINAL STUDY
Correspondence address: M. Klatka, M.D., Ph.D.,  
Department of Pediatric Endocrinology and Diabetology, 
Medical University of Lublin, Chodzki St. 2,  
20–093 Lublin, Poland;  
tel.: +48 81 756 48 56, fax: +48 81 756 48 40;  
e-mail: mariaklatka@wp.pl
Treatment of Graves’ disease with methimazole  
in children alters the proliferation of Treg cells  
and CD3+ T lymphocytes 
Maria Klatka1, Lucyna Kaszubowska2, Ewelina Grywalska3, Magdalena Wasiak4,  
Leszek Szewczyk1, Jerzy Foerster5, Marta Cyman2, Jacek Rolinski3
1Department of Pediatric Endocrinology and Diabetology, Medical University of Lublin,  
Lublin, Poland
2Department of Histology, Medical University of Gdansk, Gdansk, Poland
3Department of Clinical Immunology and Immunotherapy, Medical University of Lublin,  
Lublin, Poland
4Department of Otolaryngology and Laryngeal Oncology, Medical University of Lublin,  
Lublin, Poland
5Department of Social and Clinical Gerontology, Medical University of Gdansk, Gdansk, Poland
Abstract: Almost all cases of hyperthyroidism in children result from Graves’ disease (GD). Recent studies have 
confirmed a significant role of T regulatory cells (Tregs) in the development of autoimmune diseases. However, 
the interactions between T cell responses and Treg proliferation in GD are still poorly understood. The aim of 
this study was to assess the proliferation of Treg cells (Tregs) and CD3+ T lymphocytes isolated from 50 children 
with GD before and after treatment with the thyreostatic drug methimazole (MMI). The proliferation rates, 
measured by methyl-3H-thymidyne incorporation, of CD3+ cells and Tregs stimulated with mitogen phorbol 
12-myristate 13-acetate (PMA) were compared with those of unstimulated cells. The proliferation rates of both 
PMA-stimulated and unstimulated CD3+ cells prior to treatment with MMI were significantly higher than 
after treatment. Simultaneously, the proliferation rates of both PMA-stimulated and unstimulated Tregs were 
significantly lower before MMI treatment. Moreover, we observed higher cell proliferation rates of unstimulated 
and PMA-stimulated Tregs before the initiation of MMI therapy and after treatment in patients who had no 
relapse of hyperthyroidism. There was a positive correlation between the CD3+ cells proliferation rate before 
MMI treatment and fT3, as well as fT4 concentration in peripheral blood. The proliferation rates of CD3+ T 
cells before and after MMI treatment positively correlated with the TSI index. Thus, children suffering from 
Graves’ disease presented lower Tregs proliferative potential compared with CD3+ T cells. Cocultures of CD3+ 
T cells and Tregs showed that Tregs were not capable of efficiently inhibiting the proliferation of CD3+ T cells 
in GD patients. Conclusions. MMI treatment reduced the proliferative activity of CD3+ T cells in pediatric GD 
patients and increased the proliferation rate of Tregs. We suggest that Treg cells that are partly dysfunctional in 
GD disease are probably suppressed by CD3+ T cells and that methimazole exerts some immunomodulatory 
effects. (Folia Histochemica et Cytobiologica 2014, Vol. 52, No. 1, 69–77)
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Introduction
Hyperthyroidism affects over 2% of the population, 
and is 5–10 times more common in women than in 
men [1]. Hyperthyroidism in children and adolescents 
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has unique effects on growth and development, in 
addition to causing many of the same symptoms as 
in adults. Graves’ disease (GD) occurs in approxi-
mately 0.02 percent of children (1 in 5000) and is 
almost always the cause of hyperthyroidism in this 
age group [2].
Recent investigations have confirmed the crucial 
role of T regulatory cells (Tregs) in the development 
of autoaggressive diseases, including autoimmune 
thyroid disease (AITD) [3]. Treg cells are a subset of 
CD4+ T cells that express high levels of the CD25 
molecule and transcription factor forkhead box P3 
(FOXP3). Treg cells make up 5–10% of peripheral 
CD4+ T cells [4] and can be divided into two subpop-
ulations: the first subpopulation comprises naturally 
occurring nTreg cells (which emerge de novo from the 
embryonic/neonatal thymus and are also described 
as “thymic” Tregs or tTregs), whereasthe second 
one consists of inducible iTreg cells (induced in the 
periphery, and also described as “peripheral” Tregs 
or pTregs), whose function is to acquire a regulatory 
phenotype in response to pathogens and inflamma-
tion [5]. Treg cells exert a key homeostatic effect on 
two subpopulations of T helper (Th) cells, Th1 and 
Th2. Th1 cells secrete IFNg, IL-2, and IL-12 and are 
associa ted with cell-mediated immune responses, 
while Th2 cells secrete IL-4, IL-5, and IL-10 and 
are involved in humoral immunity. The imbalance 
between Th1 and Th2 cells caused by Treg cell dys-
function may determine the outcome of autoimmune 
diseases [4]. 
Treg cells function via negative costimulatory 
molecules, induction of anti-inflammatory signal tran-
sduction pathways in T cells and antigen-presenting 
cells, direct or indirect destruction of effector cells or 
antigen-presenting cells, and secretion of suppressive 
cytokines [6]. Tregs are involved in the maintenan-
ce of immunological self-tolerance through active 
suppression of self-reactive lymphocytes, and are 
considered an essential element in the suppression of 
autoimmune disorders. Defects in their function may 
result in chronic autoimmunity [7–11]. The impaired 
function of Treg cells in patients with Graves’ disease 
has also been reported [4]. Moreover, depletion of 
CD4+CD25+ T cells enhances the development of 
Graves’ hyperthyroidism in the mouse model [12].
Pathogenesis of autoimmune thyroid disease 
results from a loss of immune tolerance to thyroid 
antigens [3]. T cells are present in the immune reper-
toire of patients with GD, and react with appropriately 
processed peptides derived from all thyroid autoan-
tigens. These autoreactive T cells in turn stimulate 
B cells to produce thyroid-specific autoantibodies, 
which play a major role in the pathogenesis of var-
ious autoimmune diseases. In Graves’ disease, TSH 
receptor antibodies bind to receptors on the surface of 
follicular cells of the thyroid gland, activate them, and 
initiate thyroid hormone production that is not under 
the hypothalamic–hypophyseal control and results in 
hyperthyroidism. The thyroid-specific autoantibodies 
are the major targets of immunomodulatory strategies 
aimed at preventing or delaying the autoimmune 
onset of thyroid diseases [13]. The thyroid-specific 
T cells in GD primarily act as helper (CD4+ Th1) T 
cells [14]. When activated, these lymphocytes secrete 
interleukin-2 (IL-2), interferon g, and tumor necrosis 
factor (TNF), which activate cytotoxic (CD8+) T 
cells. The Th2 lymphocytes secrete IL-4 and IL-5 
and activate antithyroid antibody production. The 
CD4+ Treg lymphocytes are anti-inflammatory T 
cells, which act to diminish the activity of Th1 and 
Th2 cells [15]. Moreover, the Th1 and Th2 types of 
T helper cells interact with each other, so that a pre-
dominance of Th1 cells does not necessarily mean that 
the predominant result is apoptosis [16]. The T cell 
receptor (TCR) recognizes antigens bound to major 
histocompatibility complex (MHC) molecules (in 
humans called also human leukocyte antigens, HLA). 
This means that the T cell receptor complexes with 
the HLA molecule on the surface of an antigen-pre-
senting cell: CD8+ cells with HLA class I molecules 
and CD4+ cells with HLA class II molecules. This 
complex forms only when the appropriate antigenic 
peptide is present in the binding pocket of the HLA 
molecule. Once this complex has been formed, the 
T cell requires an additional stimulus to proliferate. 
This additional stimulus is provided by the same T cell 
and the antigen-presenting cells. If no costimulation 
occurs, the T cell may become anergic. Thyroid cells in 
autoimmune thyroid disease may express both major 
histocompatibility complex (MHC) molecules and 
costimulatory molecules, which aid in intrathyroidal 
T cell proliferation [17].
The presence of alloreactive and autoreactive 
clones in the T cell repertoire is determined by 
thymus-dependent pathways, but the activation and 
expansion of naive clonal populations are regulated in 
the peripheral lymphoid organs by antigen encounter, 
homeostatic mechanisms, and the inhibitory network 
of Treg cells [18, 19]. However, the interaction be-
tween T cell response and Treg proliferation in GD 
is still poorly understood.
Methimazole (MMI) is used as a first-line antithy-
roid drug in children and adolescents with GD [20]. 
Although it lowers the level of thyroid autoantibo-
dies—sometimes leading to long-term remission [4, 
21, 22] — little is known as yet about its influence on 
human cell-mediated immune response.
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The aim of our study was to assess in vitro the 
effects of Treg cells on the proliferation of CD3+ 
T lymphocytes in various cocultures of cells isolated 
from the peripheral blood of children with hyperthy-
reosis arising from Graves’ disease, and to describe 
the impact of MMI treatment on the proliferation of 
those cells.
Material and methods
Study group. The study group consisted of 50 previously un-
treated adolescent female patients with hyperthyroidism from 
Graves’ disease (mean age 13.42 ± 1.94; median 13.5; min–max 
11–17.2 years), hospitalized at the Department of Pediatrics, 
Division of Pediatric Endocrinology and Diabetology, Medical 
University of Lublin, Poland. The patients were diagnosed on 
the basis of clinical examination and morphological and im-
munological criteria. In the group of examined children, each 
presented a wide variety of clinical manifestations of hyperthy-
roidism at the time of diagnosis. Before beginning antithyroid 
treatment, blood samples were collected from each child for 
lymphocyte proliferation assays, and thyroid-stimulating hor-
mone (TSH), free thyroxine (fT4), and free triiodothyronine 
(fT3) hormone levels were measured. Thyrotropin receptor 
(TSHR)-stimulating immunoglobulin (TSI index) and the 
volume of the thyroid gland were also assessed.
The patients were treated with MMI at initial doses of 
0.51 ± 0.05 mg/kg body weight/day for approximately 4–6 
weeks and, after euthyroidism was achieved, blood samples 
were collected again to measure lymphocyte proliferation 
and serum hormone levels. Later, the patients received 
maintenance doses of MMI of approximately 0.1–0.2 mg/kg 
body weight/day in combination with a low dose of L-thy-
roxin, and were observed for 36 months.
None of the children had signs of infection at the time of 
investigation or for a month before sampling, and none had 
been taking drugs of known influence on the immune system. 
None of the patients had undergone blood transfusion. Indi-
viduals with a history of allergic diseases were excluded from 
the study. The research protocol was approved by the Ethics 
Committee of the Medical University of Lublin and written 
informed consent was obtained from caretakers or guardians 
on the behalf of the child participants involved in the study.
Peripheral blood mononuclear cell isolation. Mononuclear 
cells were isolated from heparinized peripheral blood sam-
ples by density gradient centrifugation on Gradisol-L (Aqua 
Medica, Warsaw, Poland). Interphase cells were collected, 
washed twice in phosphate-buffered saline (PBS), and cell 
density was adjusted to 0.5–1 × 106 cells/mL.
Magnetic separation of CD3+ T lymphocytes and T regu-
latory cells. The separation of CD3+ T lymphocytes was 
conducted using MACS Human CD3 MicroBeads Isolation 
Kit (Miltenyi Biotec, Bergisch Gladbach, Germany), while 
the separation of CD4+CD25+ cells was carried out with 
a CD4+CD25+ Regulatory T Cell Isolation Kit from the 
same manufacturer using Vario MACS Separator (Miltenyi 
Biotec). Mononuclear cells suspended in PBS without Ca2+ 
and Mg2+ ions were centrifuged and suspended in 1 mL of 
a buffer solution (PBS without Ca2+ and Mg2+ ions supple-
mented with 0.5% BSA and 2 mM EDTA). Then anti-CD3 
antibodies bound to microbeads (20 μl/107 cells) were added 
and incubated at 4°C for 15 min to isolate CD3+ T lympho-
cytes. Isolation of the T regulatory cells was conducted in 
a similar manner following the manufacturer’s instructions. 
After the designated time of incubation, cells were washed 
with a buffer solution to eliminate unbound antibodies. 
A column containing a permeable steel matrix was placed in 
a magnetic field and washed with a cold buffer. Cells were 
then centrifuged for 10 min at 300 g, suspended in 10 mL of 
buffer and applied to the column. The magnetically bound 
cells, which constituted a positive fraction, were retained in 
the column while the unbound population passed through 
it and constituted a negative fraction. The column was wa-
shed twice with cooled buffer. After removing the column 
from the magnetic field, the bound cells were retrieved by 
squeezing into a separate test tube. The positive fraction 
contained CD3+ T lymphocytes and T regulatory cells. Cells 
were suspended in 1 mL of PBS, counted, and their viability 
assessed. The purity of the obtained CD3+ T lymphocyte 
and T regulatory cell suspensions was evaluated by flow 
cytometry (FACS Calibur, Becton Dickinson, San Jose, 
CA, USA) using relevant monoclonal antibodies coupled 
with fluorochromes (BD Biosciences Pharmingen, San 
Jose, CA, USA). 
Assessment of the effect of T regulatory cells on the proli-
feration of CD3+ T lymphocytes. The assessment of the in 
vitro proliferation of CD3+ T lymphocytes was conducted 
using a thymidine incorporation assay. Tritiated thymidine 
(methyl-3H-Thymidine, Perkin Elmer, Waltham, MA, USA) 
was incorporated into DNA during the S phase of the cell 
cycle. The amount of thymidine incorporated into DNA 
depends on the number of proliferating cells. In order to 
determine the influence of T regulatory cells on the proli-
feration of CD3+ T lymphocytes, 72-hour cultures were 
set up (temperature 37°C, 5% CO2), in which the cells were 
separated into particular chambers (5×105 cells per well) 
in the following combinations: (i) CD3+ cells, (ii) CD3+ 
cells stimulated with PMA (50 ng/mL), (iii) Treg cells, (iv) 
Treg cells stimulated with PMA and (v and vi) cocultures of 
CD3+ cells and Treg cells stimulated with PMA maintained 
in ratios 1:2, 1:1 and 2:1 respectively. After 48 hours, 1μCi 
of thymidine was added to each chamber. Cells were then 
cultivated under the same conditions for the subsequent 
24 hours. At the end, cells were washed to remove free 
3H-thymidine and the proliferation rate was measured with 
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the use of a Micro Beta2 LumiJET luminescence counter 
(Perkin Elmer). The obtained results are presented as 
averages calculated from three independent measurements.
Statistical analysis. Statistical analysis of the results was 
conducted using Statistica 9.0 software. The normality of the 
distribution was evaluated by the Kolmogorov-Smirnov test. 
Differences between groups were assessed using the Mann
-Whitney U test. Pearson or Spearman correlation analyses 
were performed to estimate the relationships between the 
variables. Differences with p < 0.05 were considered stati-
stically significant. 
Results
Patients’ characteristics 
Selected clinical parameters, including fT3 and fT4 
concentrations in peripheral blood before and after 
methimazole treatment, TSI index, and thyroid gland 
volume before methimazole treatment, are presented 
in Table 1. From the 50 children included in the study, 
hyperthyroidism relapse was observed in 18 patients 
over the 3-year period, despite appropriate treatment. 
The average elapsed time between achieving euthyre-
osis and relapse was 21.5 months (± 8.9) with a range 
of between 6 and 35 months.
Lymphocyte proliferation rates before and after 
treatment with methimazole
The results of proliferation assays performed in dif-
ferent T cell culture combinations before the MMI 
treatment and after MMI-induced euthyreosis are 
presented in Figure 1. The proliferation rates of 
CD3+ cells and CD3+ cells stimulated with PMA 
before MMI treatment were significantly higher 
than after the treatment (p < 0.0001) (Figure 1A). 
The proliferation rates of Treg cells and Treg cells 
stimulated with PMA were significantly lower before 
the MMI treatment (p < 0.0001) (Figure 1B). Intere-
stingly, before MMI treatment patients suffering from 
Graves’ disease showed higher proliferation rates of 
CD3+ cells, both PMA-stimulated and unstimulated, 
compared to the Treg cells. 
After treatment with MMI, proliferation rates 
changed and the patients presented higher proli-
feration rates of Treg cells, both PMA-stimulated 
and unstimulated, and decreased proliferation rates 
of CD3+ cells (Figure 1A, B). The combination of 
CD3+ cells and Treg cells maintained in the ratio 
of 1:2 stimulated with PMA resulted in prolifera-
tion rates similar to Treg cells (significantly lower 
than before the MMI treatment). On the contrary, 
combinations of CD3+ cells and Treg cells in ratios 
of 2:1 or 1:1 stimulated with PMA resulted in pro-
liferation rates similar to those of CD3+ cells (si-
gnificantly higher than before the MMI treatment; 
p < 0.0001). These results indicate that Treg cells 
cocultured in excess with CD3+ cells (CD3+: Treg 
ratio 1:2) were capable of decreasing the prolifera-
tion rate of CD3+ cells before the treatment with 
MMI. On the other hand, methimazole reduced 
the proliferative activity of CD3+ lymphocytes in 
cocultures with Treg cells maintained in the ratio 
1:1 and 2:1 (Figure 1C).
Figure 1. Proliferation rates of CD3+ cells, Treg cells, and cocultures of CD3+ cells and Treg cells unstimulated  
(– PMA) or stimulated with PMA (+ PMA), before and after MMI treatment. A. Proliferation rates of CD3+ cells 
unstimulated or stimulated with PMA before or after MMI treatment (*p < 0.0001; #p < 0.0001). B. Proliferation rates of 
Treg cells unstimulated or stimulated with PMA before or after MMI treatment (*p < 0.0001; #p < 0.0001). C. Prolifera-
tion rates of cocultures of CD3+ cells and Treg cells maintained in the ratios: 1:2; 1:1, and 2:1 and stimulated with PMA 
before and after MMI treatment. The same significance symbols refer to the indicated pair of samples: *before and after 
MMI treatment, p < 0.0001; #before and after MMI treatment, p < 0.0001; +before and after MMI treatment, p < 0.0001
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Proliferation rates of lymphocytes isolated from 
patients with or without relapse of hyperthyroidism 
before and after treatment with methimazole
The results obtained varied, with some patients having 
relapses of hyperthyroidism during the 36-month ob-
servation period, and some having no relapse. Signifi-
cantly higher proliferation rates of Treg cells (Figure 2A) 
and of PMA-stimulated Treg cells (Figure 2B) before 
MMI treatment, as well as after the treatment, were 
observed in patients who had no relapse, in compari-
son with those who had a relapse of hyperthyroidism 
(p < 0.0001 and p < 0.05, respectively) (Figure 2). 
A similar tendency, not statistically significant, was 
observed in cocultures of CD3+ cells and Treg cells 
maintained in the ratio 1:2 stimulated with PMA, and 
of CD3+ cells and Treg cells cultured in the ratio 1:1 
stimulated with PMA. On the contrary, both CD3+ 
cells and the combination of CD3+ cells and Treg 
cells cultured in the ratio 2:1 and stimulated with PMA 
showed a tendency towards lower proliferation rates 
prior to MMI treatment and following treatment in 
patients who had no relapse, in comparison to those 
who had a relapse of hyperthyroidism (Table 2).
Relationships between lymphocyte proliferation 
rates and selected clinical parameters of the  
examined patients
Some relationships between lymphocyte proliferation 
rates and selected clinical parameters of the patients 
were observed (Table 3). A positive correlation be-
tween the proliferation rate of CD3+ lymphocytes 
prior to MMI treatment and fT3, as well as with 
fT4 concentration in peripheral blood at the time of 
the diagnosis, was found (r = 0.839, p < 0.0001 and 
r = 0.375, p < 0.01, respectively). The proliferation 
rates of CD3+ lymphocytes before and after tre-
atment with MMI were positively correlated with 
the TSI index (r = 0.968, p < 0.0001 and r = 0.522, 
p < 0.0001, respectively). There was also a positive cor-
relation between the proliferation rate of CD3+ lym-
phocytes stimulated with PMA before the MMI treat-
ment and fT4 concentration at the time of the diagnosis 
(r = 0.967, p < 0.0001). We found also a positive 
correlation between the proliferation rate of CD3 + 
lymphocytes stimulated with PMA after MMI treat-
ment and fT3 concentration at the time of the diagno-
sis (r = 0.648, p < 0.0001), as well as the TSI index 
(r = 0.619, p < 0.0001). The volume of the thyroid 
gland was positively correlated with the proliferation 
rates of cocultures of CD3+ cells and Treg lympho-
cytes maintained in the ratio 1:1 and stimulated with 
PMA, both before and after MMI treatment (r = 0.991, 
p < 0.0001 and r = 0.749, p < 0.0001, respectively). 
Discussion 
Previous studies of Graves’ disease showed a decre-
ased number of Treg cells in the peripheral blood of 
GD patients [23, 24]. Moreover, Treg cell function ap-
peared to be impaired in patients with GD. It has also 
Table 1. Selected clinical and biochemical parameters 
analyzed in patients before and after methimazole (MMI) 
treatment, presented as means ± SD
Tested parameter Before  
MMI treatment
After
MMI treatment
fT3 [pmol/L] 12.53 ± 3.91 5.91 ± 1.21
fT4 [pmol/L] 35.31 ± 13.73 16.82 ± 2.62
TSI index 7.74 ± 4.72 –
Thyroid gland volume [mL] 24.11 ± 6.41 –
Figure 2. Proliferation rates of Treg cells unstimulated (– PMA) or stimulated with PMA (+ PMA) before and after MMI 
treatment, isolated from peripheral blood of patients with or without relapse of hyperthyroidism. A. Proliferation rates of 
unstimulated Treg cells before and after MMI treatment (*p < 0.0001; #p < 0.0001). B. Proliferation rates of Treg cells 
stimulated with PMA before and after MMI treatment (*p < 0.05; #p < 0.05)
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been suggested that decreased Treg cell activity may 
be a crucial factor in the pathogenesis of GD, and that 
an increase in the number of Treg cells (or an impro-
vement in their function) might help in the remission 
of this disease [4]. Hu et al. showed that coculture of 
Treg cells and CD4+CD25-T cells (mixed at a 1:10 
ratio) with dexamethazone (DEX) for 72 h improved 
the suppressive function of Treg cells in patients with 
GD. The activity of CD4+CD25+Treg cells was 
evaluated by the proliferation rate of CD4+CD25-T 
cells with flow cytometry. Dexamethazone is a gluco-
corticoid usually employed as an immunosuppressive 
agent in the treatment of Graves’ ophthalmopathy. In 
the studies of Hu et al., dexamethazone appeared to 
affect the activity of Treg cells [4]. The immunosup-
pressive properties of DEX were also used to improve 
the effects of methimazole treatment by Mao et al. 
[25]. Their new strategy for dealing with GD involved 
Table 2. Proliferation rates of CD3+ and Treg cells unstimulated (– PMA) or stimulated with PMA (+ PMA) before  
(– MMI) and after (+ MMI) treatment with methimazole, isolated from patients with or without relapse of hyperthyroidism
Experimental conditions for evaluating lymphocyte proliferation Relapse yes n = 18 Relapse no n = 32 P value
CD3+ cells
– PMA
– MMI 
+ MMI 
48485 ± 19673
33021 ± 13469 
43069 ± 11343
30684 ± 11517 
 > 0.05
 > 0.05
CD3+ cells 
+ PMA
– MMI
+ MMI
50074 ± 11608
38515 ± 18222
51269 ± 10911
34659 ± 12075
 > 0.05
 > 0.05
Treg cells
– PMA
– MMI
+ MMI
29113 ± 5442
32748 ± 4592
36486 ± 5981
45849 ± 7887
 < 0.0001
 < 0.0001
Treg cells
+ PMA
– MMI
+ MMI
35528 ± 7024
44942 ± 9172
39476 ± 6086
55564 ± 14570
 < 0.05
 < 0.05
CD3+: Treg cells ratio 1:2
+ PMA
– MMI
+ MMI
28592 ± 7418
34353 ± 8672
31630 ± 10894
37061 ± 11096
 > 0.05
 > 0.05
CD3+: Treg cells ratio 1:1
+ PMA
– MMI
+ MMI
43356 ± 5811
34986 ± 6271
45223 ± 8619
37385 ± 10855
 > 0.05
 > 0.05
CD3+: Treg cells ratio 2:1
+ PMA
– MMI
+ MMI
44684 ± 9565
35983 ± 7468
43958 ± 10257
34013 ± 8350
 > 0.05
 > 0.05
Data are presented as means ± SD [cpm]
Table 3. Relationships between the proliferation rates of lymphocytes and selected clinical parameters of the examined 
patients
Correlated parameters Type of correlation (positive/negative) R value P value
Proliferation rate of CD3+ cells before MMI treatment and fT3 
concentration at the time of diagnosis 
Positive 0.839  < 0.0001
Proliferation rate of CD3+ cells before MMI treatment and fT4 
concentration at the time of diagnosis 
Positive 0.375  < 0.01
Proliferation rate of CD3+ cells before MMI treatment and 
TSI index at the time of diagnosis 
Positive 0.968  < 0.0001
Proliferation rate of CD3+ cells after MMI treatment and TSI 
index at the time of diagnosis 
Positive 0.522  < 0.0001
Proliferation rate of CD3+ cells stimulated with PMA before 
MMI treatment and fT4 concentration at the time of diagnosis 
Positive 0.967  < 0.0001
Proliferation rate of CD3+ cells stimulated with PMA after 
MMI treatment and fT3 concentration at the time of diagnosis 
Positive 0.648  < 0.0001
Proliferation rate of CD3+ cells stimulated with PMA after 
MMI treatment and TSI index 
Positive 0.619  < 0.0001
Proliferation rate of CD3+: Treg cells (1:1 ratio, +PMA)  
before MMI treatment and the volume of the thyroid gland 
Positive 0.991  < 0.0001
Proliferation rate of CD3+: Treg cells (1:1 ratio, +PMA)  
after MMI treatment and the volume of the thyroid gland 
Positive 0.749  < 0.0001
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treatment with methimazole (18 months) combined 
with an intrathyroid injection of DEX (3 months). 
These authors observed markedly reduced relapse 
rates of hyperthyroidism compared to treatment with 
methimazole alone (7.4% vs. 51%) during the 2-year 
follow-up period. The thyroid volume also decreased 
[25]. However, the mechanism through which dexame-
thasone reduced the relapse rate of GD was not fully 
understood [4].
The immunomodulatory function of Treg cells and 
their influence on the proliferative potential of other 
T lymphocytes were studied by Glick et al. [3]. They 
assessed Treg activity in various autoimmune thyroid 
diseases, including Graves’ disease, through the inhi-
bition of the proliferation of blood-derived T effector 
cells by Tregs in a coculture with the use of radioactive 
thymidine incorporation assay. The authors compared 
various methods of cell stimulation, and found that 
Tregs of patients with autoimmune thyroid diseases 
were less capable of inhibiting the proliferation of T 
cells as compared to healthy controls. However, the 
impairment was dependent on the type of stimulation. 
In line with our findings, Tregs appeared to be partly 
dysfunctional in these patients [3].
Our study demonstrated that Treg cells isolated 
from the peripheral blood of children suffering from 
Graves’ disease show lower proliferative potential 
than CD3+ T lymphocytes (assessed in vitro by thy-
midine incorporation assay, similarly to Glick et al. 
study [3]). Methimazole (MMI) treatment reduced 
the proliferative activity of CD3+ T cells and incre-
ased the proliferation rates of Treg cells. Moreover, 
in a model of cocultured Tregs and CD3+ T cells 
we demonstrated that Tregs were not capable of ef-
ficiently inhibiting the proliferation of CD3+ T cells 
in GD patients and that methimazole reduced the 
proliferative activity of T lymphocytes in cocultures 
with Treg cells. These results suggest that Tregs were 
partly dysfunctional in Graves’ disease and seemed 
to be suppressed by CD3+ T cells, and that MMI 
possesses some immunomodulatory effects. Our 
observations are similar to the results described by 
Hu et al. concerning the role of dexamethasone in 
immunosuppression of autoimmune thyroid diseases 
[4]. Moreover, some earlier in vitro studies suggested 
the immunomodulatory effect of methimazole on 
lymphocyte populations, although the results were 
sometimes contradictory. Bagnasco et al. [26] did not 
notice any effect of MMI on in vitro proliferation of 
T cells, whatever the activation pathway considered 
(stimulation with phytohemagglutinin, PHA, or anti
-CD3 or anti-CD2 monoclonal antibodies). Weetman 
observed an immunomodulatory effect of MMI on 
peripheral blood mononuclear cells isolated from 
normal subjects and subsequently stimulated in vitro 
with mitogens (PHA, concanavalin A, i.e. Con A or 
pokeweed mitogen) in the presence of 10–100 mmol/L 
methimazole. There was an increase in IL-2 activity 
in the culture supernatants. This effect was apparent 
between 24 and 60 h and enhanced the proliferation 
of T cells in methimazole-supplemented cultures [27]. 
Sharma et al. demonstrated that mitogen-stimulated 
lymphocytes showed increased proliferation rate in 
the presence of MMI at a concentration of 114.2 mg/ 
/mL [28]. Okabe et al. used peripheral blood lympho-
cytes from healthy individuals to study the effects of 
antithyroid drugs on Con A-induced suppressor activi-
ty of these cells against mitogen-induced proliferation 
of responder cells. They found an increase in Con 
A-stimulated suppressor function of MMI in all these 
subjects, and suggested that the enhancement in the 
suppressor activity of peripheral blood lymphocytes 
by antithyroid drugs may contribute, in part, to the 
remission of Graves’ disease [29]. However, most 
of these studies were conducted on lymphocytes 
isolated from the peripheral blood of healthy donors 
and stimulated in vitro with different mitogens in the 
presence of MMI. These results also corresponded 
to observations made by Liu et al. on mouse splenic 
lymphocytes. They observed that the proliferative 
response of mouse splenocytes to Con A was reduced 
when the mice were treated with 0.1% MMI [30].
Subsequent studies carried out by Ben-Skowronek 
et al. [31] analyzed subsets of lymphocytes isolated 
from the peripheral blood of children with the early 
phase of Graves’ disease and of lymphocytes from 
the thyroid tissue of children with the late phase of 
GD. They noticed a negative correlation between the 
duration of therapy with methimazole and the amount 
of CD3+ T cells in the thyroid interstitium. However, 
no correlation was found between lymphocyte subpo-
pulations and thyroid hormones’ serum levels prior 
to MMI treatment [31].
Our study, conducted on lymphocytes isolated 
from the peripheral blood of children suffering from 
Graves’ disease, revealed some positive correlations 
between the T cell proliferation rates prior to MMI 
treatment and fT3, as well as with fT4 concentration 
in peripheral blood at the time of the diagnosis. CD3+ 
lymphocyte proliferation rates before and after MMI 
treatment were also positively correlated with the 
TSI index. Enlargement of the thyroid gland is often 
observed in GD and depends on the duration of the 
disease [32]. In our study, the volume of the thyroid 
gland positively correlated with the proliferation 
rate of CD3+ cells and Treg lymphocytes cultured 
in ratio of 1:1 and stimulated with PMA both before 
and after MMI treatment. Our results therefore in-
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dicate a strong link between GD severity and T cell 
proliferation. 
We also observed significantly higher proliferation 
rates for Treg cells and Tregs stimulated with PMA 
both prior to and following MMI treatment in patients 
who had no relapse, than in the case of those who 
suffered a relapse of hyperthyroidism. These results 
indicate the key role of Tregs in the control of the 
course of GD. The significant role of Treg cells in the 
remission of Graves’ disease was also noticed by Hu 
et al. in their studies with dexamethazone [4].
In summary, we have shown that Treg cells isolated 
from the peripheral blood of children suffering from 
Graves’ disease have lower proliferative potential 
than CD3+ T lymphocytes. Moreover, coculturing 
Tregs and CD3+ cells showed that Tregs were not 
capable of efficiently inhibiting the proliferation of 
CD3+ lymphocytes. Only a significant excess of Tregs 
cocultured with CD3+ cells led to a decrease in the 
proliferation rate of CD3+ T cells. These observa-
tions are in line with recent studies indicating that the 
more important factor contributing to autoimmunity 
is not the absolute number of Treg cells, but rather 
the ratio of Treg to T effector cells. Antithyroid drugs, 
such as methimazole, are used as a first-line treatment 
in children and adolescents with Graves’ disease to 
normalize the concentration of thyroid hormones 
circulating in the blood [20, 33]. We found that me-
thimazole can reveal some immunomodulatory effects 
on both Treg cells and CD3+ T lymphocytes. Our 
results suggest that Treg cells seem to be suppressed 
by CD3+ T cells, and that methimazole can restore 
the partly dysfunctional suppressive function of Treg 
lymphocytes in Graves’ disease. 
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